The maker of sasineprocel, a patient-derived cell therapy, has published its preclinical work in Cell Stem Cell as it heads toward Phase 3.
The raw material for Aspen Neuroscience’s Parkinson’s therapy is a small punch of skin from the patient’s own body. Those cells are reprogrammed into induced pluripotent stem cells (iPSCs), a step Aspen describes as turning back the biological clock of the cells to a pre-disease state. They are then guided into dopaminergic neuron precursor cells (DANPCs), the early-stage cells that go on to become dopamine-producing neurons. The final product is delivered by image-guided administration into the putamen, a part of the brain where dopamine signaling needs restoring.
A quick note on that biological clock phrase, because it is easy to over-read. In longevity circles, reprogramming often conjures ideas of rejuvenating a whole body. Here the reset happens in a dish, to cells that are then turned into a different product. Nothing in the release suggests the patient themselves is made younger.
On 18 September, the San Diego company announced publication of the paper behind that process. Titled “Autologous iPSC-Derived Cell Therapy for Parkinson’s Disease: Preclinical Evaluation through Genomic Quality Controls,” it appeared in Cell Stem Cell and lays out the science behind sasineprocel (ANPD001), Aspen’s investigational therapy [1].
A batch of one
Because the cells come from the patient, every dose is effectively its own manufacturing run. Aspen says that is the payoff, since immunosuppression, which donor-derived (allogeneic) therapies require, is not needed. The flip side is that quality has to be confirmed patient by patient. Off-the-shelf approaches, such as XellSmart’s XS411 that LT covered recently, go the other way and manufacture cells in advance. Immunosuppressants carry a burden of their own, which is why avoiding them is a selling point.
That explains where much of the paper’s effort went. Using whole-genome sequencing data, Aspen says it showed reproducible characterization and manufacturing of DANPCs from multiple cell lines. Growing reprogrammed cells in a dish can, in principle, introduce genetic changes, so reading the genome of each product looks like a sensible safeguard. Repeating the exercise across multiple cell lines is meant to show the process isn’t a one-off that only worked for a lucky donor.
The paper also describes NeuriTest, an assay based on RNA sequencing that applies machine learning to gene activity data. Its job is to check whether a patient-specific cell product has the molecular traits linked to the right cell identity and to good performance in preclinical models.
Xiaokui Zhang, Aspen’s Chief Scientific Officer, said: “This work shows how we integrated whole-genome sequencing and transcriptomic analyses with functional preclinical studies to inform product quality.”
What the animals showed
Aspen reports improved motor function in preclinical Parkinson’s models. It also reports no treatment-related adverse findings in a nine-month Good Laboratory Practice (GLP) safety study in a rodent model, GLP being a formal quality standard for safety testing. The company says these data supported advancement into its ongoing Phase 1/2a ASPIRO clinical trial, which the release notes said was made possible by funding from the California Institute for Regenerative Medicine.
The trial status deserves a careful read. The release headline says the therapy is now entering Phase 3.
“As we enter Phase 3, it is an honor to share the early research that formed the strong foundation for the high-tech and high-quality development of sasineprocel, translating personalized cell therapy from scientific promise into clinical development,” Zhang said.
The same release also refers to the ongoing Phase 1/2a study. It doesn’t spell out how the two fit together, so the exact stage should be confirmed with the company.
Some limits need stating plainly. Rodent results are not human results, and this paper is about manufacturing and quality control rather than patient outcomes. Aspen’s own disclaimer says ANPD001 is investigational and not approved by the FDA, and that the company does not offer compassionate use or expanded access programs. The company describes it as the most advanced autologous investigational cell therapy in the United States for Parkinson’s, which is its own claim.
Rebuilding rather than topping up
Parkinson’s takes hold as dopamine-producing neurons are lost over time. Aspen believes sasineprocel has the potential to be disease-modifying, replacing those lost neurons and aiming to reconstruct the neural circuitry that has gone missing, to slow or halt progression. It is a single-dose treatment, which would be a very different proposition from managing symptoms for decades.
For longevity, that is the interesting bet. Neurodegeneration is one of the things that decides whether later decades are lived independently, and regenerative medicine’s central promise is replacing what wears out in an aging body. The catch is that a personalized product raises the questions our XellSmart coverage explored on cost and scale. The release doesn’t address what a patient-by-patient approach would cost or how long each batch takes to make. Those answers will matter as much as the science if the therapy reaches late-stage trials.
